Hormone receptor positive breast cancer has both estrogen receptor positive (ER+) and progesterone receptor positive (PR+) tumor receptor status. Compounds that regulate ER or PR expression, oppose the production of estrogen in the body (i.e., oppose aromatase) or inhibit estrogen binding to estrogen receptors are among those used to treat this type of breast cancer. Hormone receptor positive tumors tend to metastasize first to the bone.
Breast cancer patients with ER+/PR+ tumors have the most favorable prognosis compared to the other estrogen/progesterone subtypes (ER+/PR-, ER-/PR+, ER-/PR-). However, large breast size is associated with reduced breast cancer survival in women with ER+ breast cancer, independent of body mass index (BMI). Because this is the most hormonally driven subtype, hormone receptor positive breast cancer survivors have the greatest opportunity to influence their prognosis through diet, exercise and other lifestyle choices that can influence estrogen and other hormone levels.
We have elected not to try to summarize the statistics concerning the risk of recurrence for ER+/PR+ disease here because it varies greatly depending on numerous factors. Specific data concerning relapse and survival can be found in the studies below.
Below are links to recent studies on this topic. For a more complete list of studies, please click on ER+/PR+. Please also see our articles on hormone receptor positive breast cancer (which describes ER+/PR+ disease) and what ER+/PR+ breast cancer patients and survivors should eat.